Johnson & Johnson raises 2026 guidance, but is 23 times earnings fair?
FROM THE WIRE · FINANCE.YAHOO.COM
Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month. It now expects full-year sales of about $101.2 billion at the midpoint, a little higher than its July outlook, and slightly higher adjusted earnings per share too. The company is one of the 10 No-Brainer…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA raised guidance from a large healthcare group is relevant, but the quarter was less solid.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01J&J now expects full-year sales of about $101.2 billion at the midpoint.
- 02Third-quarter sales grew 5.9% to $25.4 billion.
- 03Adjusted earnings per share fell 7.5% to $2.59.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets